GlobalRPh Renal Dosing Masterv6.6
GlobalRPh source record

Levocetirizine

Local RX List renal extractBase record retrieved 2026-09-05See the evidence for this drug2 sources available - open source summaries, references and comparisons
READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
Printed CrCl bands overlap at 30 and 50

The RX renal bands share their 30 and 50 mL/min endpoints. Two printed ranges therefore touch the same exact boundary.

Before applying: Do not let software choose an interval at an ambiguous endpoint. Reconcile the exact product label and local policy; retain the pediatric and dialysis restrictions.

Also check: Printed CrCl bands overlap at 30 and 50

Rxlist source

GlobalRPh RX List - XYZAL

Product / population
XYZAL oral levocetirizine; numeric adjustment applies only from age 12.
Renal measure
CrCl, mL/min; ambiguous shared endpoints at 30 and 50 in printed bands.

RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.

Renal dosing, restrictions and evidence limits

For adults and patients >=12 years, the printed CrCl bands recommend: 50-80 mL/min, 2.5 mg once daily; 30-50, 2.5 mg every other day; 10-30, 2.5 mg twice weekly, every 3-4 days. The printed boundaries overlap at exactly 50 and 30; resolve these with the current label/local protocol rather than silently choosing a band. Do not use with CrCl <10 or hemodialysis. Children 6 months through 11 years with impaired renal function are contraindicated. These oral levocetirizine instructions are not the IV cetirizine QUZYTTIR regimen.

Source revision: Source revision date not established in selected retrieval. | Retrieved: 2026-09-07. Retrieval date is not the revision date.

Source: https://globalrph.com/rx-list/xyzal-drug/

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Preserved GlobalRPh source

Preserved original GlobalRPh source

Preserved historical content; not revalidated as current prescribing guidance.

Renal method: Read the measure and population stated in the original source sections.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - XYZAL

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

XYZAL oral levocetirizine; numeric adjustment applies only from age 12.

Renal method: CrCl, mL/min; ambiguous shared endpoints at 30 and 50 in printed bands.
Retrieved: 2026-09-07

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

ambiguous threshold

Printed CrCl bands overlap at 30 and 50

The RX renal bands share their 30 and 50 mL/min endpoints. Two printed ranges therefore touch the same exact boundary.

How to use this: Do not let software choose an interval at an ambiguous endpoint. Reconcile the exact product label and local policy; retain the pediatric and dialysis restrictions.

GlobalRPh RX List - XYZAL

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeGlobalRPh RX List - XYZAL
Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. This is not a byte-for-byte HTML archive. Original source: https://globalrph.com/renal/levocetirizine/

Clinical and product context

Levocetirizine is the active enantiomer of cetirizine and a selective H1-receptor antagonist. The source describes antihistamine activity in animal and human studies and treatment of uncomplicated skin manifestations of chronic idiopathic urticaria from age 6 years. Its historical generic-label discussion excludes ages 6 months to 5 years because of UCB marketing exclusivity; that statement is retained as historical source context, not as a current regulatory determination.

Scored 5 mg tablets permit a 2.5 mg dose. May be taken with or without food.

GRPH-levocetirizine-01 · Source section: Clinical and product contextRenal section finder

Usual dosing

Age 12 years or older: 5 mg once daily in the evening; some patients respond adequately to 2.5 mg.

Age 6-11 years: 2.5 mg once daily in the evening; do not exceed this dose. A 5 mg dose produces approximately twice the exposure observed in adults.

Age 6 months to 5 years: the source does not supply a dose in the historical generic-label section.

GRPH-levocetirizine-02 · Source section: Usual dosingRenal section finder

Renal Dosing

Adults and adolescents at least 12 years old:

  • CrCl 50-80 mL/min: 2.5 mg once daily.
  • CrCl 30-50: 2.5 mg every other day.
  • CrCl 10-30: 2.5 mg twice weekly, every 3-4 days.

Hepatic impairment alone requires no adjustment; adjust for renal impairment when both are present.

GRPH-levocetirizine-03 · Source section: Renal DosingRenal section finder

Hemodialysis

Patients with end-stage renal disease (CrCl below 10 mL/min) and patients undergoing hemodialysis must not receive levocetirizine.

GRPH-levocetirizine-04 · Source section: HemodialysisRenal section finder
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - XYZAL

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · XYZAL oral levocetirizine; numeric adjustment applies only from age 12.

Renal method: CrCl, mL/min; ambiguous shared endpoints at 30 and 50 in printed bands.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

For adults and patients >=12 years, the printed CrCl bands recommend: 50-80 mL/min, 2.5 mg once daily; 30-50, 2.5 mg every other day; 10-30, 2.5 mg twice weekly, every 3-4 days. The printed boundaries overlap at exactly 50 and 30; resolve these with the current label/local protocol rather than silently choosing a band. Do not use with CrCl <10 or hemodialysis. Children 6 months through 11 years with impaired renal function are contraindicated. These oral levocetirizine instructions are not the IV cetirizine QUZYTTIR regimen.

RDM35-rxlist-levocetirizine-76c45e1b42-C1 · Source locator: Renal impairment; dosage; warnings; pharmacokinetics, as identified in the selected retrieval.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/xyzal-drug/
Retrieved
2026-09-07
Renal-function method
CrCl, mL/min; ambiguous shared endpoints at 30 and 50 in printed bands.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
605c271505ffc6572b186a17df51477c7fcefe7cf05e750d0f9fbfe8c1a65979

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/levocetirizine/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
ed41c94ba0b7c9e8771126c79971c751fb310d4b0cead0cc14a6d4a8ba0a71e7
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report